Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade by unknown
POSTER PRESENTATION Open Access
Unique changes in the TCR repertoire of tumor-
infiltrating lymphocytes underlie the synergy of
radiotherapy with CTLA-4 blockade
Karsten Pilones1*, Ryan Emerson2, Silvia Formenti1, Harlan Robins3, Sandra Demaria1
From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014
Background
Checkpoint blockade is increasingly becoming a valuable
immunotherapeutic tool in the management of advanced
malignancies. Monoclonal antibodies (mAb) that target
CTLA-4 have significantly extended survival of patients
with metastatic melanoma, however the number of
responders remain low. We have previously shown in the
4T1 mouse tumor model that resistance to anti-CTLA-4
therapy can be overcome by concurrent local radiotherapy
(RT) (Demaria et al 2005 Clin Can Res 11:728). Improved
response was, in part, the result of radiation’s ability to
promote priming, and enhance homing of effector cyto-
toxic T cells to the tumor and their interactions with
tumor cells (Matsumura et al 2008 J Immunol 181;
Ruocco et al 2012 J Clin Invest 122:10). Here we used high
throughput sequencing of T cell receptor (TCR) b chain to
interrogate the breadth and depth of tumor infiltrating
lymphocytes (TILs) repertoire changes in 4T1 tumors
after treatment with anti-CTLA-4 therapy given in
conjunction with radiotherapy.
Methods
Balb/c mice were inoculated s.c. with 4T1 cells and thir-
teen days later, when tumors became palpable, randomly
assigned to one of 4 treatment groups (n = 5 mice/group):
control, RT alone, anti-CTLA-4 alone or RT+anti-
CTLA-4. RT was given in 2 fractions of 12 Gy on days 13
and 14 post-tumor inoculation. Anti-CTLA-4 mAb (Clone
9H10) was given i.p. on days 15, 18 and 21. Tumors were
harvested on day 22 for high throughput sequencing of
TCRb CDR3 regions performed using the ImmunoSEQ
platform.
Results
Data indicate distinct non-overlapping effects of the com-
bination treatment. CTLA-4 blockade increased clonality
and significantly expanded the top 5 most frequent
clonotypes. On the other hand, radiation augmented TIL
numbers and broadened their repertoire by selective
expansion of the top 6-20 clones. Importantly, analysis of
Vb/Jb usage landscape showed that the combined treat-
ment generated the most dramatic change from baseline
with the expansion of several unique Vb/Jb combinations
not seen in tumor treated with RT or CTLA-4 blockade
alone.
Conclusions
Overall, data indicate that tumor rejection induced by RT
+anti-CTLA-4 is associated with both quantitative and
qualitative changes in the TIL repertoire. They also sug-
gest that a broader repertoire of tumor-specific T cells
may be critical for therapeutic success and is achieved by
complementary effects of RT, which induces antigenic
spread, and CTLA-4 blockade, which drives expansion of
selected clones.
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